Search results
Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT
Zacks via Yahoo Finance· 11 months agoResults from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve...
Eli Lilly's Migraine Candidate Flunks Head-To-Head Study With Pfizer's Newly Acquired Drug
Benzinga via Yahoo Finance· 11 months agoEli Lilly And Co (NYSE: LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality...
Menstrual Migraine: Role of Estrogen and Self-Care Tips
Verywell Health via Yahoo News· 8 months agoMenstrual migraines develop around a person's menstrual period, typically manifesting a couple of...
Key Features of Cluster Headache vs. Migraine Symptoms
Verywell Health via Yahoo News· 6 months agoCluster headaches and migraines are complex headache disorders associated with significant and...
One Woman Shares How She Found Some Migraine Relief – After Experiencing the Debilitating Disease...
SheKnows via Yahoo News· 4 months agoAmanda, a 35-year-old mother, outdoor enthusiast and electrical engineer, will always remember May...
Eli Lilly's Migraine Drug Infringed Teva's Patents, Ordered To Pay $176M
Benzinga via Yahoo Finance· 1 year agoA federal jury has asked Eli Lilly And Company (NYSE: LLY) to pay Teva Pharmaceuticals International...
These Drugs Are the New First Line of Defense Against Migraine
Verywell Health via Yahoo News· 1 month agoIllustration by Julie Bang for Verywell Health Fact checked by Nick Blackmer Key Takeaways CGRP...
9 Proven Ways to Treat and Prevent Migraines
Men's Health via Yahoo News· 2 years agoIf you've ever had a migraine, you know the feeling of wanting to put a drill to your head to somehow rid yourself of the pain, pressure, and throbbing....
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
Zacks via Yahoo Finance· 9 months agoFollowing the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor...
Eli Lilly's migraine drug fails to prove superiority to Pfizer's
Reuters via Yahoo News· 11 months agoThe three-month study, which involved 580 patients, was the first-of-its-kind to compare the two...